OpGen Announces Acquisition of Preferred Stock by David Lazar
March 25, 2024 16:05 ET
|
OpGen, Inc.
David Lazar invests $3 million in Preferred StockNew OpGen Board of Directors appointedDavid Lazar will take over as CEO of OpGenOpGen settles outstanding liabilities with EIB ROCKVILLE, Md., March ...
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
November 14, 2023 16:30 ET
|
OpGen, Inc.
Total revenue for the first nine months of 2023 was approximately $2.35 million compared to approximately $1.89 million in the first nine months of 2022Implemented certain cash management initiatives,...
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds
October 12, 2023 12:32 ET
|
OpGen, Inc.
ROCKVILLE, Md., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to...
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 16:15 ET
|
OpGen, Inc.
Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D...
OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
August 07, 2023 07:30 ET
|
OpGen, Inc.
Single nucleotide polymorphism (SNP) analysis module and interpretation of plasmids now availableAdded reporting customized for the needs of hospital epidemiologists Signed first large commercial...
OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement
August 03, 2023 08:00 ET
|
OpGen, Inc.
Signed contract amendment is part of an overall strategic priority collaboration in the fight against AMR using Unyvero A30 platform in LMICsNext phase to cover full AMR assay and cartridge...
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
August 03, 2023 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter...
OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
July 19, 2023 07:30 ET
|
OpGen, Inc.
All milestones successfully met, including antibiotic stewardship module, mobile and cloud-based data access as well as comprehensive next generation sequencing resultsTriggers additional milestone...
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
June 26, 2023 07:30 ET
|
OpGen, Inc.
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification and use of genomic variants for the diagnosis of antibiotic resistant bacteria.The opposition division of...
OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments
June 22, 2023 07:30 ET
|
OpGen, Inc.
Following final assembly and successful testing, a batch of ten Unyvero A30 instrument systems has been receivedLatest C-Series Unyvero A30 instruments optimized for series production and clinical...